Regenxbio Competitors and Similar CompaniesClear all

Regenxbio's competitors and similar companies include Evotec, BlueRock Therapeutics, ProQR Therapeutics and Asklepios BioPharmaceutical.

	Regenxbio Regenxbio is a clinical-stage biotechnology company providing gene therapy product candidates for the treatment of retinal, metabolic, and neurodegenerative diseases.	Evotec Evotec is a biotechnology company that provides drug discovery and development services.	BlueRock Therapeutics BlueRock Therapeutics is a biotechnology company that develops cell therapies.	ProQR Therapeutics ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases.	Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein.
Founding Date	Founding Date 2009	Founding Date 1993	Founding Date 2016	Founding Date 2012	Founding Date 2001
Type	Type Public	Type Public	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare biotech genetics healthtech pharma platform therapy	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech clinical research genetics pharma therapy	Tags Healthcare biotech genetics pharma therapy	Tags Healthcare biotech genetics pharma therapy
Locations	Locations Rockville, US HQ	Locations Hamburg, DE HQ Lyon, FR Toulouse, FR Göttingen, DE Halle (Westfalen), DE Köln, DE Munich, DE see more	Locations Cambridge, US HQ Toronto, CA Berlin, DE New York, US	Locations Leiden, NL HQ Cambridge, US	Locations Chapel Hill, US HQ Roslin, GB
Employees	Employees 4018% increase	Employees 4,766	Employees 477	Employees 166	Employees 5172% increase
Valuation ($)	Valuation ($) 447.8 m	Valuation ($) 1.4 b	Valuation ($) N/A	Valuation ($) 281.8 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $170.4m (FY, 2025)	Revenue (est.) €788.4m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) €15.9m (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods €622.9m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €231.1m (FY, 2025)	Gross profit N/A	Gross profit €16.3m (FY, 2025)	Gross profit N/A
Net income	Net income ($193.9m) (FY, 2025)	Net income (€103.5m) (FY, 2025)	Net income N/A	Net income (€42.2m) (FY, 2025)	Net income N/A
Funding
Total funding raised	Total funding raised $ 118.9m	Total funding raised $ 993.6m	Total funding raised $ 225m	Total funding raised $ 57.8m	Total funding raised $ 235m